AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

XERS · NASDAQ · Biotechnology

Xeris Biopharma (XERS)

Markets Recorlev, Gvoke and Keveyis while advancing formulation-based drug programs.

$8.73

After hours0.00 (0.00%)

At close$8.73(−0.80%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	48	44	41	48	54	60	60	72	74	86	83	92
Cost of revenue	8	10	6	11	14	9	9	15	11	19	13	13
Gross profit	40	34	35	38	41	51	51	57	63	67	70	80
	45	44	49	46	54	49	54	52	57	50	62	74
Research & development	5	6	8	6	6	6	8	8	7	8	9	11
Selling, general & administrative	37	38	38	40	45	40	44	44	46	48	53	61
Other expenses	3	0	3	0	3	3	3	0	3	−5	0	3
Operating income	−5	−10	−14	−8	−13	2	−3	4	7	17	8	5
	−8	−4	−4	−6	−6	−7	−6	−6	−6	−6	−6	−36
Interest income	1	1	2	1	1	1	1	1	1	1	1	1
Interest expense	7	7	7	8	8	8	7	7	7	7	7	7
Other non-operating income	1	−3	−3	−2	−2	−1	−1	−1	−1	6	−1	29
Income before tax	−13	−14	−19	−14	−19	−5	−9	−2	1	11	2	−31
Income tax expense	0	0	0	1	−3	0	0	0	0	0	0	0
Net income from continuing operations	−12	−13	−19	−15	−16	−5	−9	−2	1	11	2	−31
Net income	−12	−13	−19	−15	−16	−5	−9	−2	1	11	2	−31
EPS, basic	−$0.09	−$0.10	−$0.14	−$0.10	−$0.11	−$0.03	−$0.06	−$0.01	$0.00	$0.07	$0.01	−$0.18
EPS, diluted	−$0.09	−$0.10	−$0.14	−$0.10	−$0.11	−$0.03	−$0.06	−$0.01	$0.00	$0.06	$0.01	−$0.18
Weighted average shares, basic	138	138	141	148	149	149	152	156	178	166	171	173
Weighted average shares, diluted	138	138	141	148	149	149	152	156	178	180	178	173
EBITDA	−2	−3	−8	−3	−8	6	1	9	11	14	12	−21
Depreciation & amortization	3	3	3	3	3	3	3	3	3	3	3	3
EBIT	−6	−7	−12	−6	−11	3	−2	5	8	11	9	−24